Skip to main content
OpenTrials
Completed

NCT Number: NCT04654390

The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus

The purpose of this study is to determine the efficacy and safety of DWP16001 compared to active drug in the treatment of type 2 diabetes mellitus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

T2DM (Type 2 Diabetes Mellitus) Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

19 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

The Catholic University of Korea Bucheon St. Mary's Hospital, Republic of Korea

Bucheon-si, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 19 to 80 years
  • Subjects with 7% ≤ HbA1c ≤ 11% at Screening
  • Subjects with BMI of 20-45 kg/m2

Exclusion criteria

  • Different type of diabetes mellitus which is not T2DM (type 1 diabetes mellitus, secondary diabetes mellitus, or congenital renal glucosuria)
  • Symptoms of stress urinary incontinence, dysuria that is not controlled by medications due to neurogenic bladder or prostatic hyperplasia, anuria, oliguria, or urinary retention
  • Severe diabetes complications (proliferative diabetic retinopathy, nephropathy of stage 4 or higher, or serious diabetic neuropathy)
  • eGFR < 60 mL/min/1.73 m2
  • Severe gastrointestinal diseases: active ulcer, gastrointestinal or rectal bleeding, active inflammatory bowel syndrome, biliary duct obstruction, active gastritis that is not controlled by medication, etc.
  • Uncontrolled hypertension (SBP >180 mmHg or DBP > 110 mmHg)

Treatment and study plan

DWP16001 Amg

Drug

Tablets, Orally, Once daily

Primary outcomes

  1. Change from Visit 2(Randomization) in HbA1c level at Week 24 after administation of the IP

    Time frame: at Week 24

    HbA1c level at Week 24 after administration of the IP

Secondary outcomes

  1. Changes from Visit 2 (randomization) in HbA1c level at Weeks 6, 12, and 18 after administration of the IP

    Time frame: at weeks 6, 12, and 18

    HbA1c level at Weeks 6, 12, and 18 after administration of the IP

  2. Changes from Visit 2 (randomization) in FPG level at Weeks 6, 12, 18, and 24 after administration of the IP

    Time frame: at weeks 6, 12, 18, and 24

    FPG level at Weeks 6, 12, 18, and 24 after administration of the IP

  3. Proportions of subjects who achieved HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP

    Time frame: at weeks 6, 12, 18, and 24

    HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP

Sponsors and collaborators

Lead sponsor

Daewoong Pharmaceutical Co. LTD.

Industry

Registry information

Official study title

A Multi-center, Randomized, Double-Blind, Active-controlled, Phase3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Dec 4, 2020
Registry last updated
Apr 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.